Pharmacist-led therapeutic carbohydrate restriction as a treatment strategy for type 2 diabetes: the Pharm-TCR randomized controlled trial protocol

Cody Durrer, Sean McKelvey, Joel Singer, Alan M Batterham, James D Johnson, Jay Wortman, Jonathan P Little, Cody Durrer, Sean McKelvey, Joel Singer, Alan M Batterham, James D Johnson, Jay Wortman, Jonathan P Little

Abstract

Background: The current treatment paradigm for type 2 diabetes mellitus (T2D) typically involves use of multiple medications to lower glucose levels in hope of reducing long-term complications. However, such treatment does not necessarily address the underlying pathophysiology of the disease and very few patients achieve partial, complete, or prolonged remission of T2D after diagnosis. The therapeutic potential of nutrition has been highlighted recently based on results of clinical trials reporting remission of T2D with targeted dietary approaches. During the initial phase of such interventions that restrict carbohydrates and/or induce rapid weight loss, hypoglycemia presents a notable risk to patients. We therefore hypothesized that delivering very low-carbohydrate, low-calorie therapeutic nutrition through community pharmacies would be an innovative strategy to facilitate lowering of glycated hemoglobin (A1C) while safely reducing the use of glucose-lowering medications in T2D.

Methods: A community-based randomized controlled trial that is pragmatic in nature, following a parallel-group design will be conducted (N = 200). Participants will have an equal chance of being randomized to either a pharmacist-led, therapeutic carbohydrate restricted (Pharm-TCR) diet or guideline-based treatment as usual (TAU). Pharm-TCR involves a 12-week very low carbohydrate, calorie-restricted commercial diet plan led by pharmacists and lifestyle coaches with pharmacists responsible for managing medications in collaboration with the participants' family physicians. Main inclusion criteria are diagnosis of T2D, currently treated with glucose-lowering medications, age 30-75 years, and body mass index ≥ 30. The primary outcome is a binary measure of use of glucose-lowering medication. Secondary outcomes include A1C, anthropometrics and clinical blood markers.

Discussion: There are inherent risks involved if patients with T2D who take glucose-lowering medications follow very low carbohydrate diets. This randomized controlled trial aims to determine whether engaging community pharmacists is a safe and effective way to deliver therapeutic carbohydrate restriction and reduce/eliminate the need for glucose-lowering medications in people with T2D.

Trial registration: ClinicalTrials.gov, NCT03181165. Registered on 8 June 2017.

Keywords: A1C; Diabetes; Diet; Glucose; Insulin; Ketogenic diet; Nutrition; Pharmacy.

Conflict of interest statement

JPL and JDJ are Co-Chief Scientific Officers and SM is CEO for the Institute for Personalized Therapeutic Nutrition (IPTN), a not-for-profit organization with goals of helping prepare healthcare providers to safely implement therapeutic nutrition.

JPL is Scientific Advisor and holds shares in Metabolic Insights Inc., a for-profit company designing non-invasive metabolic monitoring tools.

Although Ideal Protein is not a partner for this research, Pharmasave pharmacies can sell Ideal Protein weight loss products.

Figures

Fig. 1
Fig. 1
Trial Flow Diagram Pharm-TCR, Pharmacist-led, therapeutic carbohydrate restricted diet; TAU, Treatment-as-usual

References

    1. International Diabetes Federation. IDF diabetes Atlas. 8th ed. Brussels: International Diabetes Federation; 2017. internal-pdf://61.113.148.147/IDF Atlas 2017.pdf.
    1. Zimmet P. The burden of type 2 diabetes: are we doing enough? Diabetes Metab. 2003;29:6S9–618. doi: 10.1016/S1262-3636(03)72783-9.
    1. Lipscombe L, Booth G, Butalia S, Dasgupta K, Eurich DT, Goldenberg R, et al. Pharmacologic glycemic management of type 2 diabetes in adults. Can J Diabetes. 2018;42:S88–103. doi: 10.1016/j.jcjd.2017.10.034.
    1. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin: response to Farooki and Schneider [15] Diabetes Care. 2006;29:1990–1991. doi: 10.2337/dc06-0997.
    1. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–322. doi: 10.1056/NEJMoa1603827.
    1. Rao AD, Kuhadiya N, Reynolds K, Fonseca VA. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all- cause mortality? Diabetes Care. 2008;31:1672–1678. doi: 10.2337/dc08-0167.
    1. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128. doi: 10.1056/NEJMoa1504720.
    1. Karter AJ, Nundy S, Parker MM, Moffet HH, Huang ES. Incidence of remission in adults with type 2 diabetes: the diabetes & aging study. Diabetes Care. 2014;37:3188–3195. doi: 10.2337/dc14-0874.
    1. World Health Organization . The role of the pharmacist in the health care system. 1994.
    1. Boulé NG, Haddad E, Kenny GP, Wells GA, Sigal RJ. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials. JAMA. 2001;286:1218–1227. doi: 10.1001/jama.286.10.1218.
    1. Turner RC, Cull CA, Frighi V, Holman RR, for the UKPDSG Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (ukpds 49) JAMA. 1999;281:2005–2012. doi: 10.1001/jama.281.21.2005.
    1. Lean MEJ, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018;391:541–551. doi: 10.1016/S0140-6736(17)33102-1.
    1. Steven S, Taylor R. Restoring normoglycaemia by use of a very low calorie diet in long- and short-duration type 2 diabetes. Diabet Med. 2015;32:1149–1155. doi: 10.1111/dme.12722.
    1. Hallberg SJ, McKenzie AL, Williams PT, Bhanpuri NH, Peters AL, Campbell WW, et al. Effectiveness and safety of a novel care model for the management of type 2 diabetes at 1 year: an open-label, non-randomized, controlled study. Diabetes Ther. 2018;9:583–612. doi: 10.1007/s13300-018-0373-9.
    1. McKenzie AL, Hallberg SJ, Creighton BC, Volk BM, Link TM, Abner MK, et al. A novel intervention including individualized nutritional recommendations reduces hemoglobin A1c level, medication use, and weight in type 2 diabetes. JMIR Diabetes. 2017;2:e5. doi: 10.2196/diabetes.6981.
    1. Taylor R, Al-Mrabeh A, Zhyzhneuskaya S, Peters C, Barnes AC, Aribisala BS, et al. Remission of human type 2 diabetes requires decrease in liver and pancreas fat content but is dependent upon capacity for β cell recovery. Cell Metab. 2018;28:547–556.e3. doi: 10.1016/j.cmet.2018.07.003.
    1. Feinman RD, Pogozelski WK, Astrup A, Bernstein RK, Fine EJ, Westman EC, et al. Dietary carbohydrate restriction as the first approach in diabetes management: critical review and evidence base. Nutrition. 2015;31:1–13. doi: 10.1016/j.nut.2014.06.011.
    1. Corley BT, Carroll RW, Hall RM, Weatherall M, Parry-Strong A, Krebs JD. Intermittent fasting in type 2 diabetes mellitus and the risk of hypoglycaemia: a randomized controlled trial. Diabet Med. 2018;35:588–594. doi: 10.1111/dme.13595.
    1. Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia. 2011;54:2506–2514. doi: 10.1007/s00125-011-2204-7.
    1. Gannon MC, Nuttall FQ. Control of blood glucose in type 2 diabetes without weight loss by modification of diet composition. Nutr Metab. 2006;3:1–8. doi: 10.1186/1743-7075-3-16.
    1. Gregg EW, Chen H, Wagenknecht LE, et al. Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA. 2012;308:2489–2496. doi: 10.1001/jama.2012.67929.
    1. Laferrère B, Teixeira J, McGinty J, Tran H, Egger JR, Colarusso A, et al. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008;93:2479–2485. doi: 10.1210/jc.2007-2851.
    1. Coast-Senior EA, Kroner BA, Kelley CL, Trilli LE. Management of patients with type 2 diabetes by pharmacists in primary care clinics. Ann Pharmacother. 1998;32:636–641. doi: 10.1345/aph.17095.
    1. Tsui EYL, Gao XJ, Zinman B. Bioelectrical impedance analysis (BIA) using bipolar foot electrodes in the assessment of body composition in type 2 diabetes mellitus. Diabet Med. 1998;15:125–128. doi: 10.1002/(SICI)1096-9136(199802)15:2<125::AID-DIA532>;2-N.
    1. Coffman CJ, Edelman D, Woolson RF. To condition or not condition? Analysing ‘change’in longitudinal randomised controlled trials. BMJ Open. 2016;6:e013096. doi: 10.1136/bmjopen-2016-013096.
    1. Feaster DJ, Mikulich-Gilbertson S, Brincks AM. Modeling site effects in the design and analysis of multi-site trials. Am J Drug Alcohol Abuse. 2011;37:383–391. doi: 10.3109/00952990.2011.600386.
    1. Doucet G, Beatty M. The cost of diabetes in Canada: the economic tsunami. Can J Diabetes. 2010;34:27–29. doi: 10.1016/S1499-2671(10)41005-9.
    1. Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122:248–256.e5. doi: 10.1016/j.amjmed.2008.09.041.
    1. Westman EC, Yancy WS, Mavropoulos JC, Marquart M, McDuffie JR. The effect of a low-carbohydrate, ketogenic diet versus a low-glycemic index diet on glycemic control in type 2 diabetes mellitus. Nutr Metab (Lond) 2008;5:36. doi: 10.1186/1743-7075-5-36.
    1. Diabetes Canada Clinical Practice Guidelines Expert Committee Diabetes Canada Clinical Practice Guidelines Expert Committee. Can J Diabetes. 2018;42(Suppl 1):S1–S5.
    1. McInnes N, Smith A, Otto R, Vandermey J, Punthakee Z, Sherifali D, et al. Piloting a remission strategy in type 2 diabetes: results of a randomized controlled trial. J Clin Endocrinol Metab. 2017;102:1596–1605. doi: 10.1210/jc.2016-3373.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다